SCHEMBL4055704

SCHEMBL4055704

CCC(C(N)=O)(c1ccccc1)C(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.49
CYP1A2 P05177 1/20 0.49
MAPT P10636 1/20 0.48
KMT2A Q03164 1/20 0.48
KCNH2 Q12809 2/20 0.45
CHRM3 P20309 2/20 0.45
LMNA P02545 1/20 0.45
CHRM2 P08172 1/20 0.45
CHRM1 P11229 1/20 0.45
KDM4E B2RXH2 1/20 0.44
CTDSP1 Q9GZU7 1/20 0.44
KIF11 P52732 3/20 0.43
CYP2C19 P33261 1/20 0.43
HIF1A Q16665 1/20 0.43
HTT P42858 1/20 0.41
GRIN2D O15399 2/20 0.40
GRIN1 Q05586 2/20 0.40
GRIN2A Q12879 2/20 0.40
GRIN2B Q13224 2/20 0.40
GRIN2C Q14957 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4558653 0.86 KMT2A (0.46) CYP2D6CYP1A2MAPTKMT2AKCNH2
SCHEMBL4058270 0.86 KIF11 (0.48) CYP2D6CYP1A2MAPTKMT2AKCNH2
SCHEMBL3726388 0.85 CYP1A2 (0.52) CYP2D6CYP1A2MAPTKMT2AKCNH2
SCHEMBL4061023 0.83 MAPT (0.43) CYP2D6CYP1A2MAPTKMT2AKCNH2
SCHEMBL29875160 0.82 KIF11 (0.44) CYP2D6CYP1A2MAPTKMT2AKCNH2
SCHEMBL12475196 0.81 CYP2D6 (0.46) CYP2D6CYP1A2MAPTKMT2AKCNH2
SCHEMBL28478140 0.81 CYP2D6 (0.45) CYP2D6CYP1A2MAPTKMT2AKCNH2
SCHEMBL4558956 0.80 KIF11 (0.46) CYP2D6CYP1A2MAPTKMT2AKCNH2
SCHEMBL4963270 0.79 KCNN4 (0.53) CYP2D6CYP1A2MAPTKMT2AKCNH2
SCHEMBL27392933 0.79 KCNH2 (0.43) CYP2D6CYP1A2MAPTKMT2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3046560-A1 STEM CELL MODULATION II University of Canberra (AU) 2016-07-27 EP disclosed
WO-2015039187-A1 STEM CELL MODULATION II UNIVERSITY OF CANBERRA (AU) 2015-03-26 WO disclosed
US-7550473-B2 Pyrimidine derivatives useful as inhibitors of PKC-theta BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-06-23 US disclosed
US-20050124640-A1 Pyrimidine derivatives useful as inhibitors of PKC-theta BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124640-A1 Pyrimidine derivatives useful as inhibitors of PKC-theta PRKCQ, PRKCZ, PRKCH CYP2D6 2160/4885CYP1A2 2261/4885MAPT 3633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.